Patent directory · USPTO A61K / A61P
Patents matching “Arrowhead Pharmaceuticals, Inc.”
89 pharma patents match "Arrowhead Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 89 pharmaceutical patents matching "Arrowhead Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
US 9752147
RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions
granted -
US 9752152
Organic compositions to treat beta-ENaC-related diseases
granted -
US 9745585
RNAi-mediated inhibition of histamine receptor H1-related conditions
granted -
US 9562230
Transferrin/transferrin receptor-mediated siRNA delivery
granted -
US 9550994
RNAI-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
granted -
US 9540643
Organic compositions to treat HSF1-related diseases
granted -
US 9526799
Low density lipoprotein receptor-mediated siRNA delivery
granted -
US 9526796
Peptide-based in vivo siRNA delivery system
granted -
US 9487556
Polyconjugates for delivery of RNAi triggers to tumor cells in vivo
granted -
US 9474804
Poly(vinyl ester) polymers for in vivo nucleic acid delivery
granted -
US 9476047
RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions
granted -
US 9476052
RNAi inhibition of alpha-ENaC expression
granted -
US 9452221
Poly(acrylate) polymers for in vivo nucleic acid delivery
granted -
US 9453220
RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders
granted -
US 9447419
RNAi-mediated inhibition of tumor necrosis factor α-related conditions
granted -
US 9422556
RNAi-related inhibition of TNF-alpha signaling pathway for treatment of ocular angiogenesis
granted -
US 9376683
Organic compositions to treat beta-ENaC-related diseases
granted